NCT03585348View on ClinicalTrials.gov

Provider Variability in the Use of Neuromuscular Blocking Drugs and Reversal

CompletedOBSERVATIONAL
Enrollment

265,537

Participants

Timeline

Start Date

June 29, 2018

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions
Neuromuscular BlockadeResidual Curarisation, PostoperativeSurgery Under General Anaesthesia
Interventions
OTHER

Neuromuscular blocking agents

Neuromuscular blocking agent ED95 equivalent dose by provider

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

lead

Beth Israel Deaconess Medical Center

OTHER

NCT03585348 - Provider Variability in the Use of Neuromuscular Blocking Drugs and Reversal | Biotech Hunter | Biotech Hunter